A genome-wide CRISPR screening identifies targets that drive tolerogenic dendritic cells
Abstract
Tolerogenic dendritic cells (TolDCs) contribute to immune tolerance and have demonstrated therapeutic potential in early clinical studies of autoimmune diseases. However, the key molecular pathways driving their differentiation and tolerogenic phenotype remain elusive. Here, we investigated the molecular mechanisms underlying the functional status of TolDCs in response to different tolerizing agents and identified CD86 as a consistent and robust marker downregulated in tolerogenic state. CD86 is functionally required for TolDC-mediated suppression of T cell proliferation and cytokine secretion, supporting its use as a surrogate marker of tolerogenic potential. Leveraging CD86 expression as a readout, we performed a genome-wide CRISPR-Cas9 knockout screen and characterized genes associated with TolDC phenotypes. This approach positions UBE2L6 as a regulator of CD86 expression through modulation of an ISG15-USP18-associated pathway, implicating its involvement in tolerogenic functions. These findings describe therapeutically targetable pathways to promote immune tolerance.
Related
- Tolerogenic Programming Promotes Human Cytomegalovirus Permissiveness in Dendritic Cells
- Tissue retention of dendritic cells drives age-associated protective tolerogenic lymphoid structures
- Tolerogenic dendritic cells attenuate collagen-induced arthritis through a mucosal immunity–gut microbiota–butyrate axis
- Comparative screening identifies gga-miR-204 as a nutrient-responsive miRNA that targets MAP1LC3B and promotes infectious bursal disease virus replication in HD11 cells
- 699 A CRISPR-Cas9 screen identifies negative regulators of CXCL9 expression by dendritic cells
BibTeX
@article{li2026genomewide,
title = {{A genome-wide CRISPR screening identifies targets that drive tolerogenic dendritic cells}},
author = {Xiaoguang Li and Tiankai Han and Liang Chen and Megha Suresh and Fedik Rahimov and Chao Gao and Jing Wang and Renze Ma and Joshua D. Stender and Kanstantsin Katlinski},
journal = {Cell Reports},
year = {2026},
month = nov,
doi = {10.1016/j.celrep.2026.118212},
url = {https://linkinghub.elsevier.com/retrieve/pii/S221112472601291X},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - A genome-wide CRISPR screening identifies targets that drive tolerogenic dendritic cells
AU - Xiaoguang Li
AU - Tiankai Han
AU - Liang Chen
AU - Megha Suresh
AU - Fedik Rahimov
AU - Chao Gao
AU - Jing Wang
AU - Renze Ma
AU - Joshua D. Stender
AU - Kanstantsin Katlinski
PY - 2026
DA - 2026/11/01
JO - Cell Reports
DO - 10.1016/j.celrep.2026.118212
UR - https://linkinghub.elsevier.com/retrieve/pii/S221112472601291X
AB - Tolerogenic dendritic cells (TolDCs) contribute to immune tolerance and have demonstrated therapeutic potential in early clinical studies of autoimmune diseases. However, the key molecular pathways driving their differentiation and tolerogenic phenotype remain elusive. Here, we investigated the molecular mechanisms underlying the functional status of TolDCs in response to different tolerizing agents and identified CD86 as a consistent and robust marker downregulated in tolerogenic state. CD86 is functionally required for TolDC-mediated suppression of T cell proliferation and cytokine secretion, supporting its use as a surrogate marker of tolerogenic potential. Leveraging CD86 expression as a readout, we performed a genome-wide CRISPR-Cas9 knockout screen and characterized genes associated with TolDC phenotypes. This approach positions UBE2L6 as a regulator of CD86 expression through modulation of an ISG15-USP18-associated pathway, implicating its involvement in tolerogenic functions. These findings describe therapeutically targetable pathways to promote immune tolerance.
SN - 2211-1247
ER -